Sorafenib and Mesenchymal Stem Cell Therapy: A Promising Approach for Treatment of HCC
المؤلفون المشاركون
Hajighasemlou, Saieh
Nikbakht, Mohsen
Pakzad, Saeedreza
Muhammadnejad, Samad
Gharibzadeh, Safoora
Mirmoghtadaei, Milad
Zafari, Fariba
Seyhoun, Iman
Ai, Jafar
Verdi, Javad
المصدر
Evidence-Based Complementary and Alternative Medicine
العدد
المجلد 2020، العدد 2020 (31 ديسمبر/كانون الأول 2020)، ص ص. 1-8، 8ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2020-06-15
دولة النشر
مصر
عدد الصفحات
8
التخصصات الرئيسية
الملخص EN
Hepatocellular carcinoma (HCC) is the fifth most commonly diagnosed cancer and the second most common cause of cancer-related death worldwide.
Sorafenib (Sora) is used as a targeted therapy for HCC treatment.
Mesenchymal stem cells (MSCs) are applied as a new approach to fight malignancies.
Drug resistance and side effects are the major concerns with Sora administration.
The effect of using the combination of sorafenib and MSCs on tumor regression in xenograft HCC models was evaluated in this study.
Methods and Materials.
Human hepatocellular carcinoma cell lines (HepG2) were subcutaneously implanted into the flank of 18 nude mice.
The animals were randomly divided into six groups (n = 3); each received Sora (oral), MSCs (IV injection), MSCs (local injection), Sora + MSCs (IV injection), Sora + MSCs (local injection), or no treatment (the control group).
Six weeks after tumor implantation, the mice were scarified and tumoral tissues were resected in their entirety.
Histopathological and immunohistochemical evaluations were used to measure tumor proliferation and angiogenesis.
Apoptotic cells were quantified using the TUNEL assay.
Results.
No significant difference was found in the tumor grade among the treatment groups.
Differentiation features of the tumoral cells were histopathologically insignificant in all the groups.
Tumor necrosis was highest in the hpMSC (local) + Sora group.
Tumor cell proliferation was reduced in hpMSC (local) + Sora-treated and hpMSC (IV) + Sora-treated mice compared with the other groups.
Apoptotic-positive cells occupied a greater proportion in the Sora, hpMSC (IV) + Sora, and hpMSC (local) + Sora groups.
Conclusion.
A combination of chemotherapy and MSC can yield to more favorable results in the treatment of HCC.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Hajighasemlou, Saieh& Nikbakht, Mohsen& Pakzad, Saeedreza& Muhammadnejad, Samad& Gharibzadeh, Safoora& Mirmoghtadaei, Milad…[et al.]. 2020. Sorafenib and Mesenchymal Stem Cell Therapy: A Promising Approach for Treatment of HCC. Evidence-Based Complementary and Alternative Medicine،Vol. 2020, no. 2020, pp.1-8.
https://search.emarefa.net/detail/BIM-1158628
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Hajighasemlou, Saieh…[et al.]. Sorafenib and Mesenchymal Stem Cell Therapy: A Promising Approach for Treatment of HCC. Evidence-Based Complementary and Alternative Medicine No. 2020 (2020), pp.1-8.
https://search.emarefa.net/detail/BIM-1158628
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Hajighasemlou, Saieh& Nikbakht, Mohsen& Pakzad, Saeedreza& Muhammadnejad, Samad& Gharibzadeh, Safoora& Mirmoghtadaei, Milad…[et al.]. Sorafenib and Mesenchymal Stem Cell Therapy: A Promising Approach for Treatment of HCC. Evidence-Based Complementary and Alternative Medicine. 2020. Vol. 2020, no. 2020, pp.1-8.
https://search.emarefa.net/detail/BIM-1158628
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1158628
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر